General characteristics of the pooled patients
| Variable . | Value . |
|---|---|
| Total no. of patients | 3455 |
| Female, % | 41.5 |
| Mean age, y | 73.6 |
| IPSS-R risk, % | |
| Very low | 22.49 |
| Low | 67.07 |
| Total | 89.55 |
| RS+, % | 67.39 |
| Prior ESA exposure, % | 76.41 |
| Variable . | Value . |
|---|---|
| Total no. of patients | 3455 |
| Female, % | 41.5 |
| Mean age, y | 73.6 |
| IPSS-R risk, % | |
| Very low | 22.49 |
| Low | 67.07 |
| Total | 89.55 |
| RS+, % | 67.39 |
| Prior ESA exposure, % | 76.41 |
Percentages are calculated based on pooled patient-level data across all included studies. IPSS-R risk categories were reported when available; Total IPSS-R (very low + low) reflects the proportion of patients with LR-MDS per IPSS-R. ESA history refers to patients with any previous exposure to ESAs before luspatercept treatment.